| 38th week of 2022 patent applcation highlights part 25 |
| Patent application number | Title | Published |
|---|
| 20220298092 | METHOD FOR PREPARATION OF 2,5-DIMETHYLPHENOL BY SELECTIVE CATALYTIC CONVERSION OF LIGNIN - The present disclosure discloses a method for preparing 2,5-dimethylphenol by selective catalytic conversion of lignin, relates to the technical field of chemistry, and includes the following steps: mixing lignin, a catalyst, and ethanol, and then carrying out a catalytic conversion reaction of lignin under the gaseous supercritical conditions of ethanol; and cooling the reaction product by quenching after the completion of reaction, and then subjecting it to separation and extraction to obtain 2,5-dimethylphenol. The catalyst comprises a modified sepiolite carrier, an active metal Mo, and auxiliary agents Zr and Fe. The process of the present disclosure is simple, and the prepared catalyst is a solid catalyst, which avoids problems of difficult recovery, serious environmental pollution and equipment corrosion caused by the use of homogeneous organic acid-base catalysts. | 2022-09-22 |
| 20220298093 | METHODS OF ETHERIFICATION - Embodiments of the present disclosure are directed towards methods of etherification including reducing templates of a zeolite catalyst to provide a reduced template zeolite catalyst having from 3 to 15 weight percent weight percent of templates maintained following calcination of zeolite catalyst; and contacting the reduced template zeolite catalyst with an olefin and an alcohol to produce a monoalkyl ether. | 2022-09-22 |
| 20220298094 | Process for preparing methacrolein from formaldehyde and propionaldehyde and preparation plant for the purpose - A process and a preparation plant prepares methacrolein from formaldehyde and propionaldehyde, in presence of water and a homogeneous catalyst based at least on an acid and a base. A reaction mixture is introduced into a methacrolein workup plant and separated in a first distillation column, into a first distillation mixture in a gas phase at the top and a second distillation mixture in a liquid phase at the bottom. The first distillation mixture is condensed and, in a first phase separator, the organic phase and the aqueous phase of the condensate are separated from one another. The aqueous phase is introduced into a second distillation column, that is not part of the methacrolein workup plant, and is separated into a third distillation mixture in a gas phase at the top and a fourth distillation mixture at the bottom. The third distillation mixture is introduced into the methacrolein workup plant. | 2022-09-22 |
| 20220298095 | Production of Acetic Acid through Cryogenic Separation of Syngas - A system and method for producing acetic acid, including dry reforming methane with carbon dioxide to give syngas, cryogenically separating carbon monoxide from the syngas giving a first stream including primarily carbon monoxide and a second stream including carbon monoxide and hydrogen. The method includes synthesizing methanol from the second stream via hydrogenation of carbon monoxide in the second stream, synthesizing dimethyl ether from the methanol, and generating acetic acid from the dimethyl ether and first-stream carbon monoxide. | 2022-09-22 |
| 20220298096 | METHOD FOR CO-PRODUCTION OF CARBOXYLIC ACID AND EPSILON-CAPROLACTONE BASED ON AEROBIC OXIDATION - The present invention discloses a newly high-efficiency method for co-production of carboxylic acid and ε-caprolactone based on the aerobic oxidation, that is, under the developed catalytic system, the aldehyde is oxidized to corresponding carboxylic acid while cyclohexanone is oxidized to ε-caprolactone, realizes the co-production of carboxylic acid and ε-caprolactone. The salient features of this method include the use of cheap and readily available substrates, mild reaction conditions, environmentally friendly, and easy operation. It can realize the co-production of carboxylic acid and high value-added ε-caprolactone. | 2022-09-22 |
| 20220298097 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY USING COMBINED CATALYST OF ARYL BIDENTATE PHOSPHINE LIGAND - Disclosed is a method for preparing an organic carboxylic ester by using a combined catalyst of an aryl bidentate phosphine ligand. The method includes subjecting a terminal olefin, carbon monoxide, and an alcohol to a hydroesterification reaction in the presence of a combined catalyst of a palladium compound, an aryl bidentate phosphine ligand, and an acidic additive, to generate an organic carboxylic ester having one more carbon atom than the terminal olefin. | 2022-09-22 |
| 20220298098 | HALOGENATED COMPOUNDS, PROCESS AND USES THEREOF - The present disclosure relates to halogenated fatty acid lactylates, in particular to chlorinated fatty acid lactylates. | 2022-09-22 |
| 20220298099 | SYNTHESIS OF OMECAMTIV MECARBIL - Provided herein are synthetic methods for the preparation of intermediates that are utilized in the synthesis of omecamtiv mecarbil dihydrochloride. | 2022-09-22 |
| 20220298100 | DISTILLED CASHEW NUT SHELL LIQUID BASED, WATER THINABLE PHENALKAMINE AS CURING AGENT FOR EPOXY PAINT COMPOSITIONS - A water-Soluble phenalkamine curing agent including a water-soluble polyamine which is a reaction product of: (a) an unsaturated dicarboxylic acid modified distilled CNSL molecule; and (b) a water-soluble polyamine with aldehyde. The water soluble Mannich base is a reaction product of a polyamine containing at least two amino groups with a phenolic compound, with aid of an aldehyde. The dicarboxylic acid modified distilled CNSL intermediate is produce by diel alder reaction on side chain of cardanol which is renewable biomass. | 2022-09-22 |
| 20220298101 | NEW TELESCOPING SYNTHESES OF 2-METHOXYMETHYL-P-PHENYLENEDIAMINE - The invention relates to processes for preparing 2-methoxymethyl-p-phenylenediamine (I), cosmetically acceptable salts thereof, or mixtures thereof. | 2022-09-22 |
| 20220298102 | BICYCLIC COMPOUNDS - Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating deseases, such as cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD. | 2022-09-22 |
| 20220298103 | ANTI-FUNGALS TARGETING THE SYNTHESIS OF FUNGAL SHINGOLIPIDS - The present invention provides a compound having the structure: | 2022-09-22 |
| 20220298104 | METHOD OF PREPARING ACRYLONITRILE DIMER - Provided is a method of preparing an acrylonitrile dimer including: supplying an acrylonitrile monomer, a phosphorus-based catalyst, and an alcohol solvent to a reactor to perform a dimerization reaction to produce dimerized reactants (S | 2022-09-22 |
| 20220298105 | 2-CYANOACRYLATE COMPOUND AND ADHESIVE COMPOSITION - A 2-cyanoacrylate compound represented by Formula (1) and an adhesive composition containing the 2-cyanoacrylate compound represented by Formula (1). In Formula (1), R | 2022-09-22 |
| 20220298106 | IMPROVED PHOTOCHEMICAL SYNTHESIS OF VITAMIN D3 USING SENSITIZERS - The present invention discloses an improved photochemical synthesis of vitamin D3 from 7-dehydrocholesterol alone or in combination with sterol precursors in presence of the photosensitizer of Formula I in high yield and with reduced levels of impurities. | 2022-09-22 |
| 20220298107 | SUBSTITUTED UREA DIHYDROOROTATE DEHYDROGENASE INHIBITORS - Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: | 2022-09-22 |
| 20220298108 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF - A cocrystal containing the 1′R-diastereomer and the 1′S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1′R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments. | 2022-09-22 |
| 20220298109 | TWO-STEP SYNTHESIS OF PYRROLE COMPOUNDS FROM FURAN COMPOUNDS - Pyrrole compounds are produced by contacting a furan compound, a solid acid catalyst, and water to form a reaction mixture containing a γ-dicarbonyl compound, and then contacting the γ-dicarbonyl compound with ammonia or an ammonium salt to form a reaction product mixture containing the pyrrole compound. A representative pyrrole compound that can be synthesized using these processes is 2,5-dimethylpyrrole. | 2022-09-22 |
| 20220298110 | HEPATITIS B CAPSID ASSEMBLY MODULATORS - Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B. | 2022-09-22 |
| 20220298111 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE - The present disclosure relates to compounds, compositions and supplements that are capable of treating obesity. The disclosure further relates to methods of treating obesity in a subject in need thereof. | 2022-09-22 |
| 20220298112 | N-(PHENYL)-Indole-3-Sulfonamide Derivatives And Related Compounds As GPR17 Modulators For Treating CNS Disorders Such As Multiple Sclerosis - Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis. | 2022-09-22 |
| 20220298113 | BENZYLOXY PYRIDINE DERIVATIVES AND USES THEREOF - The present specification discloses a novel benzyloxy pyridine derivative compound represented by Chemical Formula 1, a salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and novel uses thereof. The uses comprise the uses in the preparation of a composition for activating autophagy, a composition for activating p62 protein, a composition for inducing oligomerization of p62 protein, or a composition for ameliorating, preventing or treating a disease caused by misfolded protein. | 2022-09-22 |
| 20220298114 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use. | 2022-09-22 |
| 20220298115 | SMALL MOLECULE INHIBITORS OF ACETYL COENZYME A SYNTHETASE SHORT CHAIN 2 (ACSS2) - The present invention relates to compounds of formula (I). The compounds may be used to modulate the acetyl coenzyme A synthetase short chain | 2022-09-22 |
| 20220298116 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF ELTROMBOPAG OR SALT THEREOF - Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5′-Chloro-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid alkaline metal salt of formula: wherein A is an alkaline metal. | 2022-09-22 |
| 20220298117 | CRYSTALLINE FORMS OF [3-(4- {2-BUTYL-1-[4-(4-CHLORO-PHENOXY)-PHENYL]-1H-IMIDAZOL-4-YL} -PHENOXY)-PROPYL]-DIETHYL-AMINE - The present invention relates to crystalline forms of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine (“COMPOUND I”) useful in the treatment of RAGE mediated diseases. | 2022-09-22 |
| 20220298118 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME - Provided is a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of diseases involving ATX. A carboxylic acid compound represented by the following formula (1) or a pharmacologically acceptable salt thereof: | 2022-09-22 |
| 20220298119 | METHYLQUINAZOLINONE DERIVATIVES - The invention provides a novel compound having the general formula (I) | 2022-09-22 |
| 20220298120 | ALKYNYL QUINAZOLINE COMPOUNDS - The present disclosure relates to compounds of Formula (I′): | 2022-09-22 |
| 20220298121 | AMINE TERMINATED PREPOLYMER AND COMPOSITION COMPRISING THE SAME - The invention relates to an amine terminated prepolymer and to a curable composition containing this prepolymer. These compositions are used to make sealants, coatings or adhesives useful in the field of construction, public works and civil engineering. | 2022-09-22 |
| 20220298122 | PROCESS FOR PREPARING CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACID COMPOUNDS - Improved methods and intermediates thereof for preparing carbamoyloxy methyl triazole cyclohexyl acid compounds are described. These compounds are useful as LPA antagonists. Formula (I). | 2022-09-22 |
| 20220298123 | TRIAZINANE DERIVATIVES AND METHODS OF MAKING THEM - The present invention is directed to compounds represented by the formula I: wherein R | 2022-09-22 |
| 20220298124 | PROCESS FOR THE PREPARATION OF CLC-1 CHLORIDE CHANNEL INHIBITORS - This disclosure relates to an improved chemical process for making compounds which are CIC-1 chloride channel inhibitors. | 2022-09-22 |
| 20220298125 | 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL) PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS - A compound of formula (I) or a salt thereof are provided: | 2022-09-22 |
| 20220298126 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES - The present invention relates to a novel method for preparing 2-(phenylimino)-3-alkyl-1,3-thiazolidin-4-ones of the general formula (I) | 2022-09-22 |
| 20220298127 | BICYCLIC HETEROARYL DERIVATIVES AND PREPARATION AND USES THEREOF - The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans. | 2022-09-22 |
| 20220298128 | INTEGRATED PROCESS AND PLANT FOR MAKING STYRENE AND PROPENE OXIDE - An integrated process for making styrene and propene oxide which comprises the steps:
| 2022-09-22 |
| 20220298129 | PREPARATION METHOD OF (5-FLUORO-2,3-DIHYDROBENZOFURAN-4-YL)METHANAMINE OR ITS SALT, AND INTERMEDIATES THEREOF - The present invention provides a preparation method of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine or a salt thereof, which uses 4-fluoro-3-methylphenol as the starting material, and is carried out through the steps of bromination, O-alkylation, cyclization, bromination, azidation or ammonolysis, and reduction. The reaction route of the present invention has simple synthesis process, convenient operation, high yield, and is environmentally friendly. The prepared (5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine can be used as an intermediate in pharmaceuticals and fine chemicals. | 2022-09-22 |
| 20220298130 | ORGANIC ELECTRONIC DEVICE - Embodiments of the present invention relate to an organic electronic device capable of ensuring high luminous efficiency, low driving voltage and high heat resistance, and improving color purity or lifespan. | 2022-09-22 |
| 20220298131 | METHOD OF MAKING GLYCEROL CARBONATE (METH)ACRYLATE AND CURABLE COMPOSITIONS BASED THEREON - Glycerol carbonate methacrylate may be prepared by reacting glycerol monomethacrylate and a carbonate such as a dialkyl carbonate in the presence of a catalyst and may be combined with an actinic radiation-curable oligomer, such as a (meth)acrylate-functionalized oligomer, and possibly other components to provide compositions capable of being cured, for example by exposure to actinic radiation, to obtain polymeric materials, such as 3D printed articles. The glycerol carbonate methacrylate reduces the viscosity of the composition, which may in the absence of the glycerol carbonate methacrylate be too high for the curable composition to be readily processed at room temperature, but additionally can impart a variety of other useful attributes to the curable compositions and cured products derived therefrom. | 2022-09-22 |
| 20220298132 | PROCESS AND SYSTEM FOR THE PRODUCTION OF ETHYLENE CARBONATE AND/OR ETHYLENE GLYCOL - The invention relates to a process for producing ethylene carbonate and/or ethylene glycol, which comprises the following steps: a) supplying an overhead absorber stream withdrawn from an absorber to a vapor-liquid separator to yield an aqueous bottoms stream and a recycle gas stream; b) supplying an aqueous process stream comprising one or more impurities to a distillation apparatus to yield an overhead impurities stream and a purified aqueous process stream, wherein the aqueous process stream supplied to the distillation apparatus comprises at least a portion of the aqueous bottoms stream withdrawn from the vapor-liquid separator, wherein the overhead impurities stream is supplied to a condenser and is cooled to a temperature in the range of from 5 to 95° C., wherein the cooled overhead impurities stream is split into a reflux stream which is recycled to the distillation apparatus and an overhead impurities stream; and further steps c) and d). | 2022-09-22 |
| 20220298133 | OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR - This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M | 2022-09-22 |
| 20220298134 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER - The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I)) | 2022-09-22 |
| 20220298135 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS - The present invention relates to novel aminopyridine derivatives of the general formula (I) and pharmaceutical compositions comprising these compounds, as well as their therapeutic use, particularly as neuropeptide FF (NPFF) receptor antagonists, including, e.g., for the treatment or prevention of pain, opioid-induced hyperalgesia, or addiction. | 2022-09-22 |
| 20220298136 | PROCESS FOR SYNTHESIS OF PYRAZOLIDINONE COMPOUNDS - A process for the synthesis of pyrazolidinone, particularly alkyl 2-(3-chloropyridin-2-yl)-5-oxo-pyrazolidine-3-carboxylate (pyrazolidinone) compound, is provided. The process is simple, economical, and produces alkyl 2-(3-chloropyridin-2-yl)-5-oxo-pyrazolidine-3-carboxylate with a comparatively high yields. | 2022-09-22 |
| 20220298137 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS - Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: | 2022-09-22 |
| 20220298138 | ENZYME INHIBITORS - The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2 | 2022-09-22 |
| 20220298139 | IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF - A compound represented by formula I are provided. The stereoisomer, racemate, tautomer, isotopic label, prodrug or a pharmaceutically acceptable salt of the compound, and a pharmaceutical composition containing the compound, a preparation method, and medical use of the compound are further provided. The structure is as shown in formula I. | 2022-09-22 |
| 20220298140 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention belongs to the field of chemical medicines, and particularly relates to a 2,4-disubstituted pyrimidine derivative, a preparation method therefor and a use thereof. The present invention provides a 2,4-disubstituted pyrimidine derivative, the structural formula of which is as shown in formula I. The present invention also provides a preparation method for the 2,4-disubstituted pyrimidine derivative and a use thereof. The 2,4-disubstituted pyrimidine derivative provided by the present invention can be used as a kinase inhibitor with double functional targets of JAK2 and FLT3, or a kinase inhibitor with independent functional targets of JAK2 or FLT3, thus providing a new choice for preparing a multi-target inhibitor. | 2022-09-22 |
| 20220298141 | ENZYME INHIBITORS - The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein. | 2022-09-22 |
| 20220298142 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS - 5,6-disubstituted 2-aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology. | 2022-09-22 |
| 20220298143 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof - The present invention provides an amide pyrazole compound used as an FGFR irreversible inhibitor, a preparation method therefor, and use thereof. Specifically, the present invention provides a compound of formula 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof, an isotopic substituent, a prodrug, or a metabolite. The compound of formula I has FGFR inhibiting activity, and can prevent or treat disorders related to FGFR activity or an expression quantity, such as, preferably, cancer. | 2022-09-22 |
| 20220298144 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF - The invention provides a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof. | 2022-09-22 |
| 20220298145 | BRAF INHIBITORS AS PARADOX BREAKERS - The invention provides a novel compound having the general formula (I) | 2022-09-22 |
| 20220298146 | HETEROCYCLIC DERIVATIVE AND USE THEREOF - Disclosed are a TAM family kinase/and Ron kinase inhibitor compound as shown in general formula (I), a pharmaceutically acceptable salt, an ester, a stereoisomer and a tautomer thereof, a pharmaceutical composition and a pharmaceutical preparation containing same, and the use thereof. The compound can selectively inhibit TAM family tyrosine kinase/and Ron kinase, and can be used for the treatment and/or prevention of diseases mediated by the abnormal expression of a receptor of TAM family kinase/and Ron kinase and/or a ligand thereof. By means of targeted inhibition of the TAM family kinase/and Ron kinase, the compound can reverse the immunosuppressive environment in a tumor microenvironment, inhibit the growth, migration and/or drug resistance performance of tumors, and exert anti-tumor immunological effects and anti-tumor efficacy. | 2022-09-22 |
| 20220298147 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE - The compounds represented by formula (1): | 2022-09-22 |
| 20220298148 | GLP-1R MODULATING COMPOUNDS - The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human. | 2022-09-22 |
| 20220298149 | ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATMENT OF DISEASES CAUSED BY VIRUS INFECTION - Isoxazole-3-carboxamide derivatives and their use in treating viral infections and diseases, such as diseases caused by viruses of the Picornaviridae family of viruses (e.g., rhinoviruses, enteroviruses, and coxsackieviruses) is described. The derivatives have good efficacy against a range of viruses, including pleconaril-resistant viral strains, and have low induction of cytochrome P4503A4 (CYP3A4). | 2022-09-22 |
| 20220298150 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF - A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R | 2022-09-22 |
| 20220298151 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES - The present disclosure relates to compounds according to Formula (I), useful for treating diseases. | 2022-09-22 |
| 20220298152 | BACE1 INHIBITORS - The present invention provides a compound of formula I | 2022-09-22 |
| 20220298153 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER - Compounds of Formula I, as shown below and defined herein: | 2022-09-22 |
| 20220298154 | PYRAZOL-3-ONES THAT ACTIVATE PRO-APOPTOTIC BAX - This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells). | 2022-09-22 |
| 20220298155 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING - The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins. | 2022-09-22 |
| 20220298156 | 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS - The invention relates to compounds as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy. | 2022-09-22 |
| 20220298157 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS - Compounds of formula (I), formula (I), processes for their production and their R use as pharmaceuticals. | 2022-09-22 |
| 20220298158 | POLYMORPH OF VENETOCLAX AND METHOD FOR PREPARING THE POLYMORPH - The present invention relates to a polymorph of venetoclax, to a process for its preparation, and to pharmaceutical compositions containing the polymorph. | 2022-09-22 |
| 20220298159 | SOLID FORMS OF {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2- -OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, A SHP2 INHIBITOR - The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof. | 2022-09-22 |
| 20220298160 | COMPOUNDS USEFUL IN HIV THERAPY - The invention relates to compounds of Formulae (I)-(II), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects. | 2022-09-22 |
| 20220298161 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer. | 2022-09-22 |
| 20220298162 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE - The invention relates to compounds of formula (I): | 2022-09-22 |
| 20220298163 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY - Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases). | 2022-09-22 |
| 20220298164 | ANTI-VIRAL DRUG - A process for the manufacture of an antiviral compound of formula (I) or a pharmaceutically acceptable salt thereof | 2022-09-22 |
| 20220298165 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process. | 2022-09-22 |
| 20220298166 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2- -TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF - The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process. | 2022-09-22 |
| 20220298167 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER - Provided herein are benzimidazole derivatives, for example, or Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease. | 2022-09-22 |
| 20220298168 | COMPOUNDS AND USES THEREOF - The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders. | 2022-09-22 |
| 20220298169 | SPIROPYRAN HYDROGELS AND LIGHT-DRIVEN EXPANSION THEREOF - Provided herein are sulfonate-based water-soluble photoswitches that, in contrast to existing systems, trigger a volumetric expansion in hydrogels upon exposure to photons; contraction is in turn observed under dark conditions in a highly reversible manner. | 2022-09-22 |
| 20220298170 | METHOD FOR SYNTHESIZING 2-((6-(HYDROXYMETHYL)CHROMENE-5-YL)OXY)-1-PHENYLETHANONE DERIVATIVE - The present invention relates to a method for synthesizing a 2-((6-(hydroxymethyl)chromen-5-yl)oxy)-1-phenylethanone derivative. When the method is used, it is possible to effectively synthesize a 2-((6-(hydroxymethyl)chromene-5-yl)oxy)-1-phenylethanone derivative. | 2022-09-22 |
| 20220298171 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF - There are disclosed, inter alia, methods of inhibiting an E1 enzyme, and compounds useful for inhibiting an E1 enzyme. | 2022-09-22 |
| 20220298172 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS - The present disclosure provides compounds, for example, a compound of Formula (I), that modulate a protein function and/or restore protein homeostasis. The disclosure provides a method of modulating a protein-mediated disease, disorder, condition, or response. Compositions, including in combination with other therapeutic agents, are provided. | 2022-09-22 |
| 20220298173 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2022-09-22 |
| 20220298174 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a compound as shown in formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor. | 2022-09-22 |
| 20220298175 | NITROGEN-CONTAINING SPIRAL ORGANIC COMPOUND AND APPLICATION THEREOF IN ORGANIC LIGHT-EMITTING DEVICE AND PANEL - A nitrogen-containing spiral organic compound is provided. The compound has a structure shown in Formula I or Formula II. A series of new TADF materials with excellent performance are developed. With the TADF materials used for mass products, the efficiency and service life of OLED devices are significantly improved and the driving voltage is reduced. | 2022-09-22 |
| 20220298176 | HETEROARYL PLASMA KALLIKREIN INHIBITORS - The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same. | 2022-09-22 |
| 20220298177 | DIVALENT METAL ASCORBATE GLYCINATE CO-SALT - A zinc ascorbate glycinate co-salt having a formula of MC | 2022-09-22 |
| 20220298178 | METHOD FOR PREPARING L-ERYTHROBIOPTERIN COMPOUND - A method for preparing an L-erythrobiopterin compound is provided. The L-erythrobiopterin compound has a structure represented by formula (I), and is mainly prepared from a compound having a structure represented by formula (II) or (III) through dihydroxylation. The preparation method of the L-erythrobiopterin compound is high in production efficiency, low in cost, environmentally friendly, and suitable for industrial production. | 2022-09-22 |
| 20220298179 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES - The present invention relates in part protective groups that can be used to reversibly protect benzoxaboroles and yield the corresponding protected complexes. The invention further relates to the use of these protective groups to protect benzoxaboroles. | 2022-09-22 |
| 20220298180 | FLUORINE-CONTAINING ETHER COMPOUND, SURFACE TREATMENT AGENT, FLUORINE-CONTAINING ETHER COMPOSITION, COATING LIQUID, ARTICLE, AND PRODUCTION METHOD THEREOF - Provided are a fluorine-containing ether compound, a fluorine-containing ether composition, and a coating liquid, which can form a surface layer having excellent durability, and an article and production method thereof having a surface layer that has excellent durability and that can maintain water and oil repellency, lubricity, and fingerprint stain removability for a long time. The fluorine-containing ether compound includes a polyfluoropolyether chain, a reactive silyl group, and a linking group that includes a group represented by *—O—C(═O)—**, in which the linking group links the polyfluoropolyether chain arranged on the * side and the reactive silyl group arranged on the ** side. | 2022-09-22 |
| 20220298181 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS - The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis. | 2022-09-22 |
| 20220298182 | Etching Composition And Method For Selectively Removing Silicon Nitride During Manufacture Of A Semiconductor Device - The disclosed and claimed subject matter is directed to an etching composition that includes (A) phosphoric acid and (B) a mixture that includes (i) a silicon-containing compound and (ii) an aqueous solvent. In some embodiments, the etching compositions include additional ingredients. The etching compositions are useful for the selective removal of silicon nitride over silicon oxide from a microelectronic device having such material(s) thereon during its manufacture. | 2022-09-22 |
| 20220298183 | BISPHOSPHITE LIGANDS BASED ON BENZOPINACOL WITH AN OPEN OUTER UNIT - Bisphosphite ligands based on benzopinacol with an open outer unit, and the use thereof in hydroformylation. | 2022-09-22 |
| 20220298184 | SELF-AGGREGATING HYDROUS PHOSPHOLIPID AND PREPARATION METHOD THEREOF - The invention belongs to the technical field of phospholipid processing, in particular to a self-aggregating hydrous phospholipid and a preparation method thereof. The self-aggregating hydrous phospholipid, the main components of the self-aggregating hydrous phospholipid are phospholipids, oil and water, the water content is 70-80 g/100 g, and the acetone-insoluble content on a dry basis is 92.5-95.5 g/100 g. Preferably, the self-aggregating hydrous phospholipid is a brown translucent fluid. The present invention is used to overcome the defects of low acetone-insoluble content of the hydrous phospholipid prepared by the existing method and the long-term dependence of the industry on the solvent method to prepare powder phospholipid, and to solve the technical problem that the hydration method powder phospholipid cannot realize industrial production. | 2022-09-22 |
| 20220298185 | Nucleoside Prodrugs and Uses Related Thereto - Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ω-oxidation, such as ω-oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers. | 2022-09-22 |
| 20220298186 | BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS - The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. | 2022-09-22 |
| 20220298187 | HETEROCYCLIC THR-B RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFOR - A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-β agonistic activity while also improving selectivity for THR-α, thereby improving pharmaceutical quality. | 2022-09-22 |
| 20220298188 | BISPHOSPHITE LIGANDS BASED ON BENZOPINACOL - Bisphosphite ligands based on benzopinacol, and the use thereof in hydroformylation. | 2022-09-22 |
| 20220298189 | LIGANDS BASED ON PHOSPHONITE PHOSPHITES - Ligands based on phosphonite phosphites, and the use thereof in hydroformylation. | 2022-09-22 |
| 20220298190 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound of Formula Ir(L | 2022-09-22 |
| 20220298191 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE - Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the same, and an electronic apparatus including the organic light-emitting device. | 2022-09-22 |
